Results from a large international survey indicated that depression worsened the systemic symptom burden for patients.
Depressive symptoms are common among patients with myeloproliferative neoplasms (MPNs), according to an international survey of patients, and researchers report that suggests depression contributes to and confounds the manifestation of the disease.
Among the 1300 respondents of the survey, nearly 1 in 4 exhibited depressive symptoms, as shown by a score of at least 3 on the Patient Health Questionnaire-2, which indicates patients at high risk of depression rather than diagnosing depression.
Notably, the survey results indicated that having worse depressive symptoms worsened the systemic symptom burden for patients. These patients scored significantly higher on the Myeloproliferative Neoplasm Symptom Assessment Form (mean 40.8 vs 24.6; P <.001), higher worst fatigue score (mean 7.8 vs 5.8; P <.001), and worse overall quality of life (mean 5.7 vs 3.1; P <.0001).
For fatigue specifically, the researchers observed differences in timing among patients. For those exhibiting depressive symptoms, they were more likely to feel fatigued all day (42.7% vs 17.5%, P <.0001), whereas patients not expressing depressive symptoms were more likely to feel fatigued at night (47% vs 35%, P <.001).
Across MPN types, higher depressive symptoms were associated with higher levels of systemic symptoms in polycythemia vera and myelofibrosis and were associated with higher levels of systemic symptoms across all but 2 constitutional symptoms in essential thrombocythemia.
“The presence of constitutional symptoms impact prognostic scoring for myelofibrosis and is a key feature in therapy response in JAK2 inhibition, indicating the importance of the presence and mitigation of these physiologic experiences,” wrote the researchers. “The association of MPN constitutional symptoms with prominent depressive symptoms suggests that heavy constitutional symptom burden leads to depressive symptoms and addressing the MPN symptom severity, through pharmacological or nonpharmacological therapies, may improve symptoms of depression.”
Of the 300 patients exhibiting depressive symptoms based on survey results, 38% had a score of 3, 29% had a score of 4, and 17% had a score of 6. These respondents were more likely to smoke(10.9% vs 5%, P = .0003), use prescription pain medication (24.4% vs 10.6%, P<.0001), use antidepressants (31.3% vs 11.9%, P <.0001), and use anxiety medications (15.4% vs 8.6%, P = .0005). They were also less likely to regularly exercise (P <.0001).
According to the researchers, the identified risk of depressive symptoms among these patients is consistent with reports of such symptoms in other hematologic malignancies, which “suggests that patients with MPN diagnosis, regardless of treatment type, have a similar risk of depressive symptoms as individuals with high risk hematologic malignancies undergoing aggressive, often intravenous treatment.”
Reference
Padrnos L, Scherber R, Geyer H, et al. Depressive symptoms and myeloproliferative neoplasms: understanding the confounding factor in a complex condition. Cancer Med. Published online September 25, 2020. doi: 10.1002/cam4.3380.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More